covid-19 vaccine licensing

covid-19 vaccine licensing

After it was found that it reduces the risk of death or dangerous symptoms by about 90%, the American pharmaceutical company Pfizer asked ، On Tuesday, US health authorities will authorize its anti-Covid-19 drug.

The move comes a few weeks after Merck submitted a request to the US Food and Drug Administration to allow its antiviral tablets to be used to treat people with COVID-19.

Experts consider oral medicines to be a valuable addition to vaccines, as part of efforts to eradicate the pandemic.

"With more than 5 million deaths and countless people affected by the deadly disease globally, there is an urgent need to provide life-saving treatment options," said a statement by Pfizer CEO Albert Burla.

"We are moving forward as quickly as possible in our efforts to make this potential treatment available to patients," he added.

Positive interim results

It is noteworthy that Pfizer is seeking to obtain a license for emergency use based on positive interim results of clinical tests between the intermediate and last stages conducted on hundreds of people, including adults with Covid who were not admitted to hospitals, who have a high risk of developing severe symptoms of the disease.

The data also showed a reduction of 89% in the rate of injuries requiring hospitalization and deaths, when treatment is started within 3 days of the onset of symptoms, and no deaths were recorded among those who received treatment. The results were similar for those who received treatment five days after the onset of symptoms. The drug is given for 5 days.

What are the benefits of flaxseed milk?